2bind Announces New Co-CEO Leadership Team
2bind GmbH, a leading contract research organization (CRO) specializing in biophysical analysis for drug discovery and antibody development, today announced a transition in its executive leadership. Dr. Thomas Schubert, Co-CEO, has decided to step down from his role, effective October 31, 2024, to pursue other opportunities and dedicate more time to his family.
2bind Opens New Headquarters
2bind GmbH Opens New Headquarters to as a Result of Quality Work and Continued Growth
Dr. Cosimo Kropp joins executive team as CBO
2bind GmbH Elevates Dr. Cosimo Kropp to Chief Business Officer
Launch of Antibody Unit with Dr. Vera Molkenthin as Director
2bind GmbH Launches Antibody Unit with Appointment of Dr. Vera Molkenthin as Director
Dr. Cosimo Kropp Hired as New Director Business Development
2bind GmbH Strengthens Business Development with Appointment of Dr. Cosimo Kropp
Regensburg Biotech Hub Combats COVID-19 with High-Tech Research Project
A collaborative research project based in Regensburg is leveraging cutting-edge technology and expertise to develop a novel drug against COVID-19. The project unites 2bind GmbH, a leading biophysical analysis company located in BioPark Regensburg, with researchers from the University of Regensburg and the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM).
2bind Supports Novel Concept Towards Prophylactic HIV-Vaccine
The federally funded interdisciplinary research project “HIVacToGC” was launched to investigate new approaches to the prevention and treatment of HIV infections.
2bind and Jena Bioscience Announce Collaboration for Enhanced Antibody Formulation Development
2bind GmbH, a leading provider of biophysical analysis tools, is pleased to announce a new collaboration with Jena Bioscience GmbH, a renowned manufacturer of high-quality reagents and tools for life science research. This partnership brings together the expertise of both companies to enhance antibody formulation development with the FORMOscreen®.
2bind Secures German Federal Funding for Battling Antibiotic Resistance
A consortium of 2bind GmbH and the University of Regensburg have successfully secured over 750.000 EUR federal funding for a research project investigating the potential of glutamine amidotransferase as novel drug targets for antibiotics.
2bind Wins 1st Place in EU-wide Call for Proposals
2bind wins first place in the EU’s Eureka Eurostars competition, together with partners from the Netherlands and Great Britain.